Truist Financial Corp Has $2.38 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Truist Financial Corp lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 12.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,808 shares of the biotechnology company’s stock after selling 1,505 shares during the period. Truist Financial Corp’s holdings in United Therapeutics were worth $2,377,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale lifted its position in shares of United Therapeutics by 54.4% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock worth $20,617,000 after buying an additional 33,338 shares during the period. Nordea Investment Management AB boosted its stake in shares of United Therapeutics by 155.2% in the 4th quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock valued at $8,427,000 after purchasing an additional 23,532 shares in the last quarter. Duality Advisers LP grew its holdings in shares of United Therapeutics by 56.1% in the 4th quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock worth $3,440,000 after purchasing an additional 5,622 shares during the last quarter. Louisiana State Employees Retirement System acquired a new stake in shares of United Therapeutics during the 4th quarter worth about $2,903,000. Finally, O Shaughnessy Asset Management LLC lifted its holdings in United Therapeutics by 4.9% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company’s stock valued at $520,000 after purchasing an additional 107 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $259.70, for a total value of $934,920.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $33,761. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $259.70, for a total transaction of $934,920.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $33,761. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Christopher Causey sold 2,240 shares of United Therapeutics stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the sale, the director now directly owns 4,185 shares in the company, valued at approximately $1,087,723.35. The disclosure for this sale can be found here. Insiders have sold 147,630 shares of company stock worth $35,089,803 in the last three months. Insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Oppenheimer upped their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. Wedbush reiterated an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. Wells Fargo & Company increased their target price on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Finally, The Goldman Sachs Group upped their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $308.78.

United Therapeutics Stock Down 1.9 %

Shares of NASDAQ:UTHR opened at $261.09 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The stock has a market cap of $11.58 billion, a price-to-earnings ratio of 12.34 and a beta of 0.54. The company has a 50 day moving average of $239.06 and a 200-day moving average of $230.10. United Therapeutics Co. has a one year low of $204.44 and a one year high of $268.21.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.86 EPS. On average, sell-side analysts forecast that United Therapeutics Co. will post 23.88 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.